Loading clinical trials...
Loading clinical trials...
This study will evaluate the association of non-alcoholic fatty liver disease and diabetes mellitus. Patients presenting in our clinic with Diabetes mellitus type 1 or 2 will receive the following examination: * Transient Elastography and Controlled Attenuation Parameter using the FibroScan * blood examination including biochemical markers The statistically calculated sample size needed is 340 patients.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
University Hospital Frankfurt
Frankfurt am Main, Hesse, Germany
Start Date
May 1, 2013
Primary Completion Date
December 31, 2019
Completion Date
December 31, 2019
Last Updated
February 3, 2021
340
ACTUAL participants
Controlled Attenuation Parameter (CAP), Echosens, Paris, France
DEVICE
FibroScan, Echosens, Paris, France
DEVICE
Lead Sponsor
Johann Wolfgang Goethe University Hospital
NCT06218589
NCT07268937
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05051527